We are live on
!
Find out more
PCA
Private Capital Advisors Portfolio holdings
AUM
$1.15B
1-Year Est. Return
43.46%
This Fund
S&P 500
This Quarter
Est. Return
+10.64%
1 Year Est. Return
+43.46%
3 Year Est. Return
+131.91%
5 Year Est. Return
+229.29%
10 Year Est. Return
+757.55%
AUM
$269M
AUM Growth
–
Cap. Flow
+$264M
Cap. Flow
% of AUM
98.02%
Top 10 Holdings %
Top 10 Hldgs %
27.65%
Holding
112
New
112
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
quarters
Top 10 Avg Time Held
0
quarters
Top 20 Avg Time Held
0
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$10.8M |
| 2 |
RH
RH
|
+$10.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$7.56M |
| 4 |
Apple
AAPL
|
+$6.29M |
| 5 |
Enterprise Products Partners
EPD
|
+$6.18M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.57% |
| 2 | Energy | 19.28% |
| 3 | Communication Services | 12.18% |
| 4 | Industrials | 9.72% |
| 5 | Technology | 7.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
RH
RH
$2.19B
| $15.6M | 5.8% |
+208,333
| New | +$10.3M |
2013 Q2
0 quarters
|
|
|
2
Celldex Therapeutics
CLDX
$2.22B
| $12.8M | 4.77% |
+54,837
| New | +$10.8M |
2013 Q2
0 quarters
|
|
|
3
BioMarin Pharmaceuticals
BMRN
$10.5B
| $6.76M | 2.51% |
+121,350
| New | +$7.56M |
2013 Q2
0 quarters
|
|
|
4
Enterprise Products Partners
EPD
$77.8B
| $6.34M | 2.36% |
+204,120
| New | +$6.18M |
2013 Q2
0 quarters
|
|
5
APA Corp
APA
$16.8B
| $5.83M | 2.16% |
+69,503
| New | +$5.52M |
2013 Q2
0 quarters
|
|
|
6
Apple
AAPL
$4.98T
| $5.79M | 2.15% |
+408,884
| New | +$6.29M |
2013 Q2
0 quarters
|
|
7
Plains All American Pipeline
PAA
$17.6B
| $5.38M | 2% |
+96,345
| New | +$5.45M |
2013 Q2
0 quarters
|
|
8
RTX Corp
RTX
$247B
| $5.38M | 2% |
+91,924
| New | +$5.43M |
2013 Q2
0 quarters
|
|
9
IBM
IBM
$217B
| $5.37M | 1.99% |
+29,396
| New | +$5.72M |
2013 Q2
0 quarters
|
|
10
Pfizer
PFE
$162B
| $5.15M | 1.91% |
+193,856
| New | +$5.36M |
2013 Q2
0 quarters
|
|
11
Union Pacific
UNP
$168B
| $4.92M | 1.83% |
+63,770
| New | +$4.81M |
2013 Q2
0 quarters
|
|
12
DELISTED
Anadarko Petroleum
APC
| $4.5M | 1.67% |
+52,350
| New | +$4.51M |
2013 Q2
0 quarters
|
|
|
CEO
13
DELISTED
CNOOC Limited
CEO
| $4.47M | 1.66% |
+26,707
| New | +$4.79M |
2013 Q2
0 quarters
|
|
14
Liberty Media Corporation Series A Common Stock
FWONA
$21.4B
| $4.32M | 1.6% |
+191,869
| New | +$4.07M |
2013 Q2
0 quarters
|
|
15
CVR Partners
UAN
$1.33B
| $4.24M | 1.57% |
+18,642
| New | +$4.59M |
2013 Q2
0 quarters
|
|
16
Eaton
ETN
$166B
| $4.21M | 1.56% |
+63,925
| New | +$4.03M |
2013 Q2
0 quarters
|
|
17
LyondellBasell Industries
LYB
$19.4B
| $4.16M | 1.54% |
+62,725
| New | +$3.96M |
2013 Q2
0 quarters
|
|
|
APL
18
DELISTED
ATLAS PIPELINE PARTNERS LP UTS
APL
| $4.14M | 1.54% |
+108,545
| New | +$4.01M |
2013 Q2
0 quarters
|
|
19
Citigroup
C
$209B
| $4.09M | 1.52% |
+85,357
| New | +$4.1M |
2013 Q2
0 quarters
|
|
20
Visa
V
$744B
| $4.06M | 1.51% |
+88,960
| New | +$3.89M |
2013 Q2
0 quarters
|
|
21
Blackstone
BX
$82.6B
| $3.97M | 1.47% |
+192,041
| New | +$4M |
2013 Q2
0 quarters
|
|
22
Lockheed Martin
LMT
$116B
| $3.95M | 1.47% |
+36,435
| New | +$3.72M |
2013 Q2
0 quarters
|
|
23
McKesson
MCK
$112B
| $3.93M | 1.46% |
+34,330
| New | +$3.82M |
2013 Q2
0 quarters
|
|
24
ExxonMobil
XOM
$716B
| $3.91M | 1.45% |
+43,247
| New | +$3.89M |
2013 Q2
0 quarters
|
|
|
DTV
25
DELISTED
DIRECTV COM STK (DE)
DTV
| $3.86M | 1.43% |
+62,610
| New | +$3.75M |
2013 Q2
0 quarters
|
|
Similar funds
WB
AIC
CFP
HT
AA
CIG
CIS
FWM
Private Capital Advisors's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Private Capital Advisors, which disclosed 112 positions worth $269M. Its ten largest holdings account for 28% of the portfolio.
Its largest position is Celldex Therapeutics: 54,837 shares worth $12.8M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, followed by Energy and Communication Services.
- Private Capital Advisors's largest Q2 2013 buy was Celldex Therapeutics: 54,837 shares worth $12.8M.
- Private Capital Advisors's ten largest holdings make up 28% of its $269M portfolio in Q2 2013.
- Private Capital Advisors disclosed 112 positions in Q2 2013, its first 13F filing on record.
Based on Private Capital Advisors's 13F filing for Q2 2013, filed 24 Jul 2013.